Targets › TFR2
1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 3; Metabolic and endocrine; next expected readout Dec 2026.
Mediates cellular uptake of transferrin-bound iron in a non-iron dependent manner. May be involved in iron metabolism, hepatocyte function and erythrocyte differentiation. (UniProt, Q9UP52)
Open in Phaseline: the race on TFR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| JCR Pharmaceuticals | Pabinafusp Alfa (JR-141) Transferrin receptor binding agent | TFRC, TFR2 | Phase 3 | Mucopolysaccharidosis II | Dec 2026 |
Mucopolysaccharidosis II (3)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.